A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Clinical trial NCT02511132 · COMPLETED
Trial details
- NCT number
- NCT02511132
- Sponsor
- Gradalis, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-10
- Primary completion
- 2018-11-12
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.